» Articles » PMID: 33727094

Cisplatin-induced Activation and Functional Modulation of Satellite Glial Cells Lead to Cytokine-mediated Modulation of Sensory Neuron Excitability

Overview
Journal Exp Neurol
Specialty Neurology
Date 2021 Mar 17
PMID 33727094
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin plays an essential role in the treatment of various cancers. Cisplatin exhibits high efficacy, but it often leads to severe neurotoxic side effects, such as chemotherapy-induced polyneuropathy (CIPN). The pathophysiology of CIPN is not fully understood. There is increasing evidence for damage to satellite glial cells (SGC) and dorsal root ganglion (DRG) neurons. We investigated the influence of cisplatin on the function of SGCs and the direct influence on DRGs. Satellite glial cells were isolated from DRG and exposed to 0.1, 1, 10, or 100 μM cisplatin for 2 h, 4 h, and 24 h. Using immunocytochemical staining and Western blot analysis, the expression of the glial fibrillary acid protein (GFAP), reactive oxygen species (ROS), and inward rectifier potassium channel 4.1 (K) was determined. An increase in the immune reactivity (IR) and protein levels of GFAP and ROS was measured, and a reduction of IR and protein level of K was detected. A decrease in these channels' current density was observed using the whole-cell patch-clamp recording. The interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) release of SGCs increased after cisplatin exposure as measured using ELISA, and interleukin-1β (IL-1β) decreased. The SGC-secreted factors in the supernatant after cisplatin treatment led to a modulation of cultured DRG neurons' excitability. Taken together, the modulation and function of different SGC proteins could be linked to a direct impact of cisplatin. Further, SGC-secreted factors influenced the excitability of sensory neurons. Overall, SGCs could be a potential target in preventing and treating chemotherapy-induced neuropathic pain.

Citing Articles

Preclinical Insights into the Role of Kir4.1 in Chronic Pain and Depression: Mechanisms and Therapeutic Potential.

Zha T, Fang X, Wan J, Chen X, Lin J, Chen Q Biomolecules. 2025; 15(2).

PMID: 40001468 PMC: 11852603. DOI: 10.3390/biom15020165.


Double-Layer Microneedle Patch Loaded with HA-PBA-QCT for Management of Paclitaxel-Induced Peripheral Neuropathic Pain.

Kong Y, Pan T, Liu B, Kuss M, Krishnan M, Alimi O Small. 2025; 21(8):e2409748.

PMID: 39888259 PMC: 11855232. DOI: 10.1002/smll.202409748.


Targeting dorsal root ganglia for chemotherapy-induced peripheral neuropathy: from bench to bedside.

Ege E, Briggi D, Vu P, Cheng J, Lin F, Xu J Ther Adv Neurol Disord. 2024; 17:17562864241252718.

PMID: 39318973 PMC: 11421407. DOI: 10.1177/17562864241252718.


Pain research in a petri dish? Advantages and limitations of neuro-glial primary cell cultures from structures of the nociceptive system.

Leisengang S Brain Behav Immun Health. 2024; 41:100854.

PMID: 39308957 PMC: 11415590. DOI: 10.1016/j.bbih.2024.100854.


Recent Advances in Biomolecular Patho-Mechanistic Pathways behind the Development and Progression of Diabetic Neuropathy.

Ratan Y, Rajput A, Pareek A, Pareek A, Kaur R, Sonia S Biomedicines. 2024; 12(7).

PMID: 39061964 PMC: 11273858. DOI: 10.3390/biomedicines12071390.